文献速递泌尿男性生殖肿瘤

HYPO-RT-PC:前列腺癌超低分割对比常规分割放疗的患者报告生活质量结局

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2021-01-11

HYPO-RT-PC 是一项在瑞典和丹麦 12 个中心开展的多中心、开放标签、随机、对照、非劣效 3 期试验,比较局限期前列腺癌常规分割与超低分割放疗的患者报告生活质量。超低分割组在放疗结束时 10 项肠道症状中有 7 项临床相关恶化比例显著更高,但此后直至 6 年两组泌尿、肠道和性功能无临床相关差异。

要点

  • 超低分割放疗结束时肠道急性症状恶化比例高于常规分割。
  • 放疗结束后的长期随访中两组泌尿、肠道和性功能无临床相关差异。
  • 6 年时总体泌尿、肠道、性困扰及整体健康生活质量组间无差异。

核心结论

  • 超低分割放疗急性毒性高于常规分割,但长期患者报告生活质量与常规分割同样耐受至治疗完成后 6 年。
  • 这些发现支持对中高危前列腺癌使用超低分割放疗。

研究设计与样本

  • HYPO-RT-PC 为多中心、开放标签、随机、对照、非劣效 3 期试验,在瑞典和丹麦 12 个中心开展。
  • 纳入组织学证实的中高危前列腺癌、年龄不超过 75 岁、WHO 体能状态 0-2 的患者。
  • 共 1180 例随机分配至常规分割组(n=591)或超低分割组(n=589),生活质量分析纳入 1165 例(常规分割 n=582,超低分割 n=583)。
  • 生活质量为次要终点,在符合方案人群中分析至放疗后 6 年,中位随访 48 个月(IQR 25-72)。

主要发现

  • 放疗结束时,两组在急性泌尿症状或问题(共 14 项)及性功能的临床相关恶化比例上无统计学显著差异。
  • 此后两组在泌尿、肠道或性功能方面无临床相关差异。

关键数值与推荐

  • 生活质量采用经验证的前列腺癌症状量表(PCSS)和欧洲癌症研究与治疗组织生活质量问卷(EORTC QLQ-C30)评估。

临床怎么用

  • 超低分割放疗可作为中高危局限期前列腺癌的放疗选择,需告知患者放疗结束时肠道急性症状可能更明显。
  • 长期患者报告生活质量与常规分割相当,支持在临床中应用超低分割方案。

局限性

  • 6 年随访时问卷完成率常规分割组为 71%(158/223)、超低分割组为 66%(146/220)。
  • 生活质量为次要终点,在符合方案人群中分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The HYPO-RT-PC trial compared conventionally fractionated radiotherapy with ultra-hypofractionated radiotherapy in patients with localised prostate cancer. Ultra-hypofractionation was non-inferior to conventional fractionation regarding 5-year failure-free survival and toxicity. We aimed to assess whether patient-reported quality of life (QOL) differs between conventional fractionation and ultra-hypofractionation up to 6 years after treatment in the HYPO-RT-PC trial. METHODS: HYPO-RT-PC is a multicentre, open-label, randomised, controlled, non-inferiority, phase 3 trial done in 12 centres (seven university hospitals and five county hospitals) in Sweden and Denmark. Inclusion criteria were histologically verified intermediate-to-high-risk prostate cancer (defined as T1c-T3a with one or two of the following risk factors: stage T3a; Gleason score ≥7; and prostate-specific antigen 10-20 ng/mL with no evidence of lymph node involvement or distant metastases), age up to 75 years, and WHO performance status 0-2. Participants were randomly assigned (1:1) to conventional fractionation (78·0 Gy in 39 fractions, 5 days per week for 8 weeks) or ultra-hypofractionation (42·7 Gy in seven fractions, 3 days per week for 2·5 weeks) via a minimisation algorithm with stratification by trial centre, T-stage, Gleason score, and prostate-specific antigen. QOL was measured using the validated Prostate Cancer Symptom Scale (PCSS) and European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) at baseline, the end of radiotherapy, months 3, 6, 12, and 24 after radiotherapy, every other year thereafter up to 10 years, and at 15 years. The primary endpoint (failure-free survival) has been reported elsewhere. Here we report QOL, a secondary endpoint analysed in the per-protocol population, up to 6 years after radiotherapy. The HYPO-RT-PC trial is registered with the ISRCTN registry, ISRCTN45905321. FINDINGS: Between July 1, 2005, and Nov 4, 2015, 1200 patients were enrolled and 1180 were randomly assigned (conventional fractionation n=591, ultra-hypofractionation n=589); 1165 patients (conventional fractionation n=582, ultra-hypofractionation n=583) were included in this QOL analysis. 158 (71%) of 223 patients in the conventional fractionation group and 146 (66%) of 220 in the ultra-hypofractionation group completed questionnaires at 6 years. The median follow-up was 48 months (IQR 25-72). In seven of ten bowel symptoms or problems the proportion of patients with clinically relevant deteriorations at the end of radiotherapy was significantly higher in the ultra-hypofractionation group than in the conventional fractionation group (stool frequency [p<0·0001], rush to toilet [p=0·0013], flatulence [p=0·0013], bowel cramp [p<0·0001], mucus [p=0·0014], blood in stool [p<0·0001], and limitation in daily activity [p=0·0014]). There were no statistically significant differences in the proportions of patients with clinically relevant acute urinary symptoms or problems (total 14 items) and sexual functioning between the two treatment groups at end of radiotherapy. Thereafter, there were no clinically relevant differences in urinary, bowel, or sexual functioning between the groups. At the 6-year follow-up there was no difference in the incidence of clinically relevant deterioration between the groups for overall urinary bother (43 [33%] of 132 for conventional fractionation vs 33 [28%] of 120 for ultra-hypofractionation; mean difference 5·1% [95% CI -4·4 to 14·6]; p=0·38), overall bowel bother (43 [33%] of 129 vs 34 [28%] of 123; 5·7% [-3·8 to 15·2]; p=0·33), overall sexual bother (75 [60%] of 126 vs 59 [50%] of 117; 9·1% [-1·4 to 19·6]; p=0·15), or global health/QOL (56 [42%] of 134 vs 46 [37%] of 125; 5·0% [-5·0 to 15·0]; p=0·41). INTERPRETATION: Although acute toxicity was higher for ultra-hypofractionation than conventional fractionation, this long-term patient-reported QOL analysis shows that ultra-hypofractionation was as well tolerated as conventional fractionation up to 6 years after completion of treatment. These findings support the use of ultra-hypofractionation radiotherapy for intermediate-to-high-risk prostate cancer. FUNDING: The Nordic Cancer Union, the Swedish Cancer Society, and the Swedish Research Council.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fransson P, Nilsson P, Gunnlaugsson A, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol. 2021. PMID: 33444529. doi:10.1016/S1470-2045(20)30581-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。